©2025 Stanford Medicine
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
Not Recruiting
Trial ID: NCT03824535
Purpose
This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with indeterminate lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers. Giving 18F-FSPG before a PET/CT scan may work better in helping researchers diagnose early lung cancer in patients with lung nodules.
Official Title
18F-FSPG PET/CT and Integrated Biomarkers for Early Lung Cancer Detection in Patients With Indeterminate Pulmonary Nodules
Stanford Investigator(s)
Carina Mari Aparici
Clinical Professor, Radiology - Rad/Nuclear Medicine
Eligibility
Inclusion Criteria:
* Pulmonary nodule between the size of 7 to 30 mm. Subjects with multiple nodules may be eligible if the dominant nodule is 7 to 30 mm
* Undergoing standard of care 18F-FDG PET imaging (for indeterminate pulmonary nodule)
* Current or former cigarette smoker, with \>= 20 pack years
* Documented informed consent
Exclusion Criteria:
* History or previous diagnosis of lung cancer
* Cancer diagnosis within the last 5 years
* Pregnant or nursing
Intervention(s):
drug: Fludeoxyglucose F-18
drug: Fluorine F 18 L-glutamate Derivative BAY94-9392
diagnostic_test: Computed Tomography
diagnostic_test: Positron Emission Tomography (PET/CT)
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mahima Goel
650-723-0371